With the exceptions of specific NHL subtypes and potentially CAR T-cell association, PD-1/PD-L1 ICBs generally do not add much clinical benefit when combined with other active agents in the R/R NHL setting. The gene discussed is PDCD1; the disease is non-Hodgkin lymphoma.